HRP960607B1 - Injectable quinolone formulations - Google Patents

Injectable quinolone formulations

Info

Publication number
HRP960607B1
HRP960607B1 HR960607A HRP960607A HRP960607B1 HR P960607 B1 HRP960607 B1 HR P960607B1 HR 960607 A HR960607 A HR 960607A HR P960607 A HRP960607 A HR P960607A HR P960607 B1 HRP960607 B1 HR P960607B1
Authority
HR
Croatia
Prior art keywords
injectable
quinolone
formulations
quinolone formulations
injectable quinolone
Prior art date
Application number
HR960607A
Other languages
English (en)
Inventor
Wayne Alan Boettner
Peter Connor Canning
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP960607(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of HRP960607A2 publication Critical patent/HRP960607A2/xx
Publication of HRP960607B1 publication Critical patent/HRP960607B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR960607A 1995-12-21 1996-12-19 Injectable quinolone formulations HRP960607B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (2)

Publication Number Publication Date
HRP960607A2 HRP960607A2 (en) 1998-06-30
HRP960607B1 true HRP960607B1 (en) 2002-06-30

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
HR960607A HRP960607B1 (en) 1995-12-21 1996-12-19 Injectable quinolone formulations

Country Status (42)

Country Link
US (1) US5811130A (bg)
EP (1) EP0868183B1 (bg)
JP (1) JP3416145B2 (bg)
KR (1) KR100402570B1 (bg)
CN (1) CN1104899C (bg)
AP (1) AP706A (bg)
AR (1) AR005147A1 (bg)
AT (1) ATE212551T1 (bg)
AU (1) AU709474B2 (bg)
BG (1) BG63933B1 (bg)
BR (1) BR9612230A (bg)
CA (1) CA2239352C (bg)
CO (1) CO4480098A1 (bg)
CZ (1) CZ293747B6 (bg)
DE (1) DE69618987T2 (bg)
DK (1) DK0868183T3 (bg)
DZ (1) DZ2146A1 (bg)
EG (1) EG24071A (bg)
ES (1) ES2167609T3 (bg)
GT (1) GT199600098A (bg)
HR (1) HRP960607B1 (bg)
HU (1) HU227918B1 (bg)
IL (1) IL124454A (bg)
IS (1) IS2010B (bg)
MA (1) MA24035A1 (bg)
MX (1) MX9805026A (bg)
MY (1) MY117109A (bg)
NO (1) NO315734B1 (bg)
NZ (2) NZ501160A (bg)
OA (1) OA10697A (bg)
PE (1) PE25798A1 (bg)
PL (1) PL186795B1 (bg)
PT (1) PT868183E (bg)
RS (1) RS49523B (bg)
RU (1) RU2141827C1 (bg)
SI (1) SI0868183T1 (bg)
SK (1) SK284412B6 (bg)
TN (1) TNSN96163A1 (bg)
TW (1) TW449475B (bg)
UA (1) UA56151C2 (bg)
WO (1) WO1997023217A1 (bg)
ZA (1) ZA9610780B (bg)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
AU2001228454A1 (en) * 2000-01-13 2001-07-24 Merck Patent G.M.B.H Pharmaceutical preparations containing 2-pyrrolidone as the dissolving intermediary
EP1356809A4 (en) * 2000-12-28 2008-05-14 Takeda Pharmaceutical SUSTAINED RELEASE PREPARATIONS
JP2005535644A (ja) * 2002-06-26 2005-11-24 ファルマシア コーポレイション 安定な非経口パレコキシブ液体製剤
ZA200700844B (en) * 2004-07-02 2009-07-29 Daiichi Seiyaku Co Quinolone-containing medicinal composition
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
LT1991201T (lt) * 2006-02-10 2018-07-25 Pari Pharma Gmbh Puškiami antibiotikai inhaliaciniam gydymui
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
PL2344129T3 (pl) 2008-10-07 2018-07-31 Horizon Orphan Llc Formulacje fluorochinolonu w aerozolu dla poprawy właściwości farmakokinetycznych
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
US10406149B2 (en) 2015-06-02 2019-09-10 Kyorin Pharmaceutical Co., Ltd. Aqueous liquid formulation
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
RU2019128568A (ru) * 2017-02-13 2021-03-15 Байер Энимэл Хельс ГмбХ Жидкая композиция, содержащая прадофлоксацин
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
AU647772B2 (en) * 1989-12-29 1994-03-31 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
HU227918B1 (en) 2012-06-28
WO1997023217A1 (en) 1997-07-03
PL328001A1 (en) 1999-01-04
UA56151C2 (uk) 2003-05-15
PE25798A1 (es) 1998-05-21
CN1104899C (zh) 2003-04-09
TW449475B (en) 2001-08-11
ATE212551T1 (de) 2002-02-15
US5811130A (en) 1998-09-22
AU7328996A (en) 1997-07-17
YU69096A (sh) 1999-06-15
HUP9903726A2 (hu) 2000-04-28
NZ320545A (en) 2000-03-27
OA10697A (en) 2001-05-04
DE69618987D1 (de) 2002-03-14
DZ2146A1 (fr) 2002-10-23
BG102542A (bg) 1999-06-30
RU2141827C1 (ru) 1999-11-27
NZ501160A (en) 2001-10-26
ES2167609T3 (es) 2002-05-16
AP9600898A0 (en) 1997-01-31
IS4755A (is) 1998-05-25
NO982842D0 (no) 1998-06-19
NO982842L (no) 1998-06-19
MA24035A1 (fr) 1997-07-01
SK284412B6 (sk) 2005-03-04
KR19990076617A (ko) 1999-10-15
BG63933B1 (bg) 2003-07-31
JPH11501331A (ja) 1999-02-02
NO315734B1 (no) 2003-10-20
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
HRP960607A2 (en) 1998-06-30
DE69618987T2 (de) 2002-11-21
MY117109A (en) 2004-05-31
CA2239352A1 (en) 1997-07-03
IL124454A0 (en) 1998-12-06
CZ193098A3 (cs) 1999-05-12
JP3416145B2 (ja) 2003-06-16
SI0868183T1 (en) 2002-04-30
DK0868183T3 (da) 2002-03-25
ZA9610780B (en) 1998-06-22
GT199600098A (es) 1998-06-12
TNSN96163A1 (fr) 2005-03-15
MX9805026A (es) 1998-09-30
CO4480098A1 (es) 1997-07-09
PL186795B1 (pl) 2004-02-27
BR9612230A (pt) 1999-07-13
EP0868183B1 (en) 2002-01-30
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
CZ293747B6 (cs) 2004-07-14
AR005147A1 (es) 1999-04-14
HUP9903726A3 (en) 2001-01-29
CA2239352C (en) 2002-06-04
IL124454A (en) 2003-10-31
IS2010B (is) 2005-05-13
SK80798A3 (en) 1999-09-10
EG24071A (en) 2008-05-11
PT868183E (pt) 2002-06-28
CN1205636A (zh) 1999-01-20
KR100402570B1 (ko) 2003-12-18

Similar Documents

Publication Publication Date Title
EG24071A (en) Injectable quinolone formulations
IL118004A0 (en) Vaccine compositions
EG24118A (en) Pharmaceutical compositions
IL117249A0 (en) Vaccine compositions
GB9616672D0 (en) Pharmaceutical compositions
GB9610359D0 (en) Pharmaceutical compositions
ZA979726B (en) Pharmaceutical compositions
GB9606429D0 (en) Pharmaceutical compositions
GB9613457D0 (en) Pharmaceutical compositions
GB9623962D0 (en) Pharmaceutical composition
GB9618376D0 (en) Pharmaceutical compositions
GB9610136D0 (en) Pharmaceutical compositions
GB9509291D0 (en) Formulations
GB9603942D0 (en) Pharmaceutical compositions
GB9606586D0 (en) Pharmaceutical compositions
SI0941095T1 (en) Improved pharmaceutical compositions
GB9624115D0 (en) Formulations
GB9509941D0 (en) Formulations
GB9510349D0 (en) Formulations
GB9508144D0 (en) Formulations
ZA962792B (en) Pharmaceutical composition
GB9626185D0 (en) Pharmaceutical composition
GB9615627D0 (en) Pharmaceutical composition
GB9611530D0 (en) Pharmaceutical composition
GB9620048D0 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20081121

Year of fee payment: 13

PBON Lapse due to non-payment of renewal fee

Effective date: 20091220